Twist Bioscience (NASDAQ:TWST) Stock: Insider Paula Green Sells 10,088 Shares

Key Points

• Insider sale: SVP Paula Green sold 10,088 Twist Bioscience shares for approximately $1.91 million, reducing her holdings by 8.64%. The sale was made to cover tax withholding tied to vested equity awards.
• Strong stock momentum: TWST rose to $205, near its 52-week high, with shares up sharply above their 50-day and 200-day moving averages. Analysts maintain a “Moderate Buy” consensus, though the average $115.27 price target is well below the current price.
• Growth but ongoing losses: Quarterly revenue increased 23.2% year over year to $118.38 million, exceeding estimates, but adjusted EPS missed expectations and the company remains unprofitable with a negative net margin.

Twist Bioscience Corporation (NASDAQ:TWST - Get Free Report) SVP Paula Green sold 10,088 shares of the stock in a transaction dated Friday, October 2nd. The shares were sold at an average price of $188.88, for a total value of $1,905,421.44. Following the transaction, the senior vice president owned 106,632 shares in the company, valued at $20,140,652.16. This trade represents a 8.64% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Paula Green also recently made the following trade(s):

• On Monday, September 21st, Paula Green sold 294 shares of Twist Bioscience stock. The stock was sold at an average price of $165.49, for a total value of $48,654.06.

Twist Bioscience Price Performance

NASDAQ TWST traded up $16.33 on Monday, reaching $205.00. 3,203,579 shares of the company's stock traded hands, compared to its average volume of 1,622,926. Twist Bioscience Corporation has a 12 month low of $23.30 and a 12 month high of $207.90. The stock has a market cap of $12.86 billion, a PE ratio of -92.34 and a beta of 2.19. The stock has a 50-day simple moving average of $136.40 and a 200 day simple moving average of $92.42. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.67 and a quick ratio of 2.38.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its earnings results on Monday, August 3rd. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.05). The business had revenue of $118.38 million for the quarter, compared to the consensus estimate of $114.55 million. Twist Bioscience had a negative net margin of 31.66% and a negative return on equity of 28.64%. Twist Bioscience's revenue for the quarter was up 23.2% on a year-over-year basis. During the same period in the prior year, the business posted $0.33 EPS. As a group, research analysts predict that Twist Bioscience Corporation will post -2.12 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of TWST. Allworth Financial LP bought a new position in Twist Bioscience during the 2nd quarter valued at approximately $62,000. Trifecta Capital Advisors LLC bought a new stake in shares of Twist Bioscience in the 2nd quarter worth approximately $63,000. Western Wealth Management LLC purchased a new position in shares of Twist Bioscience during the first quarter valued at approximately $31,000. Strs Ohio bought a new position in shares of Twist Bioscience during the first quarter valued at approximately $33,000. Finally, GAMMA Investing LLC raised its holdings in shares of Twist Bioscience by 24.4% during the second quarter. GAMMA Investing LLC now owns 943 shares of the company's stock valued at $97,000 after acquiring an additional 185 shares in the last quarter.

Wall Street Analysts Forecast Growth

TWST has been the subject of a number of recent research reports. TD Cowen reissued a "buy" rating on shares of Twist Bioscience in a research note on Monday, August 3rd. Piper Sandler raised their price target on Twist Bioscience from $85.00 to $115.00 and gave the stock an "overweight" rating in a research report on Wednesday, August 5th. Barclays lifted their price target on Twist Bioscience from $65.00 to $95.00 and gave the stock an "overweight" rating in a research note on Wednesday, June 24th. Guggenheim increased their price objective on Twist Bioscience from $107.00 to $212.00 and gave the company a "buy" rating in a research note on Thursday. Finally, Evercore cut shares of Twist Bioscience from an "outperform" rating to an "in-line" rating and set a $102.00 target price on the stock. in a report on Monday, July 6th. Eight research analysts have rated the stock with a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the company's stock. According to data from MarketBeat, Twist Bioscience has a consensus rating of "Moderate Buy" and an average target price of $115.27.

Trending Headlines about Twist Bioscience

Here are the key news stories impacting Twist Bioscience this week:

• Positive Sentiment: Twist Bioscience reported approximately 23% year-over-year revenue growth in its latest quarter, reinforcing the company’s expansion narrative and helping support bullish sentiment. Twist Bioscience stock reports 23 percent revenue growth
• Positive Sentiment: Leerink raised its price target for TWST from $120 to $160, signaling improved analyst expectations. Although the revised target remains below the recent share price, the increase may have added to buying momentum. Leerink raises target for Twist Bioscience stock
• Positive Sentiment: The stock reached a new 52-week high, reflecting strong momentum and investor demand. TWST has benefited from enthusiasm around biotechnology and synthetic-DNA markets, as well as attention from actively managed biotech funds. Twist Bioscience reaches new 52-week high
• Neutral Sentiment: CEO Emily Leproust, CFO Adam Laponis, CAO Robert Werner, SVP Paula Green and insider Dennis Cho sold shares primarily to cover tax withholding tied to vested equity awards. The transactions totaled roughly $14.3 million, but the CEO’s sales were conducted under a pre-arranged Rule 10b5-1 plan, reducing their usefulness as a signal of deteriorating business prospects. Twist Bioscience insider transaction filing
• Negative Sentiment: Valuation and profitability remain risks: the company continues to report net losses, and its latest quarterly earnings per share missed estimates despite beating revenue expectations. The sharp rally also leaves the stock well above Leerink’s revised target, increasing the potential for volatility or profit-taking.

Twist Bioscience Company Profile

Twist Bioscience Corporation NASDAQ: TWST is a biotechnology company that develops and manufactures synthetic DNA using a silicon-based production platform. Its technology is designed to enable the precise, high-throughput synthesis of DNA at smaller scale and with potentially lower material consumption than traditional methods.

The company provides synthetic DNA products and services for applications in drug discovery and development, biotechnology research, agriculture, industrial chemicals and other life sciences markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.